Real World Data Survival Outcomes of First Line Immunotherapy with Pembrolizumab in High Expressers with stage IV Non-Small Cell Lung Cancer. Radiol Oncol. 2026;60(3):450-458. Accessed September 21, 2026. https://radioloncol.com/index.php/ro/article/view/4876